Acurx Pharmaceuticals (ACXP) Short Interest Ratio & Short Volume $0.42 -0.01 (-1.37%) As of 09:30 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Acurx Pharmaceuticals Short Interest DataAcurx Pharmaceuticals (ACXP) has a short interest of 452,800 shares, representing 2.67% of the float (the number of shares available for trading by the public). This marks a 112.18% increase in short interest from the previous month. The short interest ratio (days to cover) is 1.3, indicating that it would take 1.3 days of the average trading volume of 150,675 shares to cover all short positions.Current Short Interest452,800 sharesPrevious Short Interest213,400 sharesChange Vs. Previous Month+112.18%Dollar Volume Sold Short$321,261.60Short Interest Ratio1.3 Days to CoverLast Record DateFebruary 28, 2025Outstanding Shares22,043,000 sharesFloat Size16,960,000 sharesShort Percent of Float2.67%Today's Trading Volume208,990 sharesAverage Trading Volume150,675 sharesToday's Volume Vs. Average139% Short Selling Acurx Pharmaceuticals? Sign up to receive the latest short interest report for Acurx Pharmaceuticals and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartACXP Short Interest Over TimeACXP Days to Cover Over TimeACXP Percentage of Float Shorted Over Time Remove Ads Acurx Pharmaceuticals Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 2/28/2025452,800 shares $321,261.60 +112.2%2.7%1.3 $0.71 2/15/2025213,400 shares $158,342.80 -31.8%1.3%0.6 $0.74 1/31/2025313,100 shares $228,750.86 -52.2%1.9%1.2 $0.73 1/15/2025655,000 shares $471,534.50 +41.9%4.0%2.5 $0.72 12/31/2024461,600 shares $375,742.40 -8.1%2.8%2.2 $0.81 12/15/2024502,100 shares $429,345.71 +8.2%3.5%4 $0.86 11/30/2024463,900 shares $579,875.00 +4.6%3.2%4.1 $1.25 11/15/2024443,700 shares $763,164.00 -6.5%3.1%5.9 $1.72 10/31/2024474,500 shares $892,060.00 -5.5%3.4%10.1 $1.88 10/15/2024501,900 shares $1.02 million +2.1%3.6%10.2 $2.04 Get the Latest News and Ratings for ACXP and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Acurx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 9/30/2024491,700 shares $934,230.00 +2.8%3.6%7.6 $1.90 9/15/2024478,300 shares $975,732.00 +5.6%3.5%7.8 $2.04 8/31/2024452,800 shares $996,160.00 +3.1%3.3%7.7 $2.20 8/15/2024439,400 shares $896,376.00 -5.4%3.2%8.1 $2.04 7/31/2024464,300 shares $1.00 million -17.3%3.5%7.8 $2.16 7/15/2024561,200 shares $1.34 million -8.6%4.2%9.4 $2.39 6/30/2024614,100 shares $1.38 million -7.1%4.6%10.9 $2.25 6/15/2024661,200 shares $1.61 million -4.0%4.9%10.6 $2.43 5/31/2024688,400 shares $1.73 million +15.6%5.1%9.2 $2.51 5/15/2024595,600 shares $1.34 million -3.2%4.4%7.4 $2.25 4/30/2024615,500 shares $1.38 million +6.3%4.7%7.4 $2.25 4/15/2024579,100 shares $946,828.50 +71.6%4.8%5.6 $1.64 3/31/2024337,400 shares $826,630.00 +14.6%2.8%2 $2.45 3/15/2024294,500 shares $801,040.00 +0.9%2.5%1.7 $2.72 2/29/2024291,900 shares $837,753.00 -3.2%2.6%1.3 $2.87 2/15/2024301,500 shares $919,575.00 -12.3%2.7%1.3 $3.05 1/31/2024343,700 shares $1.12 million +41.1%3.0%1.4 $3.27 1/15/2024243,600 shares $1.13 million -18.5%2.1%0.7 $4.63 12/31/2023298,800 shares $1.14 million -32.0%2.6%0.5 $3.83 12/15/2023439,100 shares $1.54 million -21.0%3.9%0.5 $3.50 11/30/2023555,800 shares $1.96 million -14.3%5.0%0.7 $3.52 11/15/2023648,300 shares $2.23 million -31.5%5.8%0.9 $3.44 10/31/2023946,100 shares $5.06 million -9.0%9.0%1.3 $5.35 10/15/20231,040,000 shares $4.51 million +10,197.0%9.9%1.6 $4.34 9/30/202310,100 shares $15,150.00 +50.8%0.1%0 $1.50 9/15/20236,700 shares $11,859.00 -51.1%0.1%0.2 $1.77 8/31/202313,700 shares $26,441.00 +95.7%0.1%0.4 $1.93 8/15/20237,000 shares $11,200.00 -63.0%0.1%0.2 $1.60 7/31/202318,900 shares $38,367.00 +42.1%0.2%0.7 $2.03 7/15/202313,300 shares $28,462.00 +58.3%0.1%0.5 $2.14Trump’s Final Plan (Ad)Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’s secret plan to trigger the greatest transfer of wealth since FDR and LBJ – trillions of dollars could be redistributed.Click here for the full story. 6/30/20238,400 shares $22,260.00 -27.6%0.1%0.3 $2.65 6/15/202311,600 shares $31,900.00 +39.8%0.1%0.5 $2.75 5/31/20238,300 shares $25,730.00 -60.9%0.1%0.3 $3.10 5/15/202321,200 shares $71,868.00 -7.0%0.2%0.7 $3.39 4/30/202322,800 shares $68,172.00 +4.1%0.3%0.7 $2.99 4/15/202321,900 shares $64,824.00 -25.5%0.2%0.7 $2.96 3/31/202329,400 shares $101,724.00 -52.8%0.3%0.9 $3.46 3/15/202362,300 shares $212,443.00 +150.2%0.7%1.8 $3.41 2/28/202324,900 shares $82,419.00 -33.8%0.3%0.7 $3.31 2/15/202337,600 shares $131,976.00 +78.2%0.4%1.2 $3.51 1/31/202321,100 shares $75,960.00 -7.9%0.2%0.7 $3.60 1/15/202322,900 shares $97,325.00 -3.4%0.2%0.9 $4.25 12/30/202223,700 shares $94,326.00 -18.0%0.3%1 $3.98 12/15/202228,900 shares $112,710.00 +26.8%0.3%1.4 $3.90 11/30/202222,800 shares $72,732.00 -1.3%0.2%1 $3.19 11/15/202223,100 shares $72,072.00 +5.5%0.3%1 $3.12 10/31/202221,900 shares $67,452.00 -27.2%0.2%0.8 $3.08 10/15/202230,100 shares $88,795.00 -22.2%0.3%1.1 $2.95 9/30/202238,700 shares $116,100.00 +45.5%0.4%1.5 $3.00 9/15/202226,600 shares $103,740.00 +10.8%0.3%1 $3.90 8/31/202224,000 shares $83,760.00 -34.1%0.3%0.9 $3.49 8/15/202236,400 shares $164,164.00 -13.5%0.4%1.6 $4.51 7/31/202242,100 shares $150,718.00 +89.6%0.5%2.1 $3.58 7/15/202222,200 shares $80,475.00 -43.9%N/A1.4 $3.63 6/30/202239,600 shares $150,084.00 -29.9%N/A2.5 $3.79 6/15/202256,500 shares $213,570.00 +16.3%N/A3.2 $3.78 5/31/202248,600 shares $130,734.00 -1.2%N/A2.8 $2.69 5/15/202249,200 shares $133,332.00 +39.4%N/A2.7 $2.71 4/30/202235,300 shares $131,669.00 -59.2%N/A2 $3.73 4/15/202286,600 shares $346,400.00 -22.3%N/A3.3 $4.00 3/31/2022111,400 shares $365,392.00 +136.5%N/A4 $3.28 3/15/202247,100 shares $175,683.00 +9.0%N/A1.6 $3.73 2/28/202243,200 shares $157,209.12 -53.7%N/A1.4 $3.64 2/15/202293,300 shares $375,999.00 -4.3%N/A2.6 $4.03 1/31/202297,500 shares $405,600.00 -28.8%N/A2.3 $4.16 1/15/2022137,000 shares $627,460.00 -16.2%N/A3 $4.58 12/31/2021163,400 shares $706,116.76 -6.0%N/A3.6 $4.32 12/15/2021173,800 shares $716,056.00 +52.2%N/A2.9 $4.12 11/30/2021114,200 shares $548,160.00 -17.1%N/A1.9 $4.80 11/15/2021137,700 shares $684,369.00 +14.9%N/A2.2 $4.97 10/29/2021119,800 shares $599,000.00 +17.7%N/A1.7 $5.00 10/15/2021101,800 shares $499,838.00 -4.9%N/A1.2 $4.91 9/30/2021107,000 shares $549,980.00 +11.2%N/A0.8 $5.14 9/15/202196,200 shares $485,810.00 +24.9%N/A0.2 $5.05 8/31/202177,000 shares $398,090.00 -35.9%N/A0.1 $5.17 8/13/2021120,100 shares $576,480.00 No ChangeN/A0.1 $4.80 ACXP Short Interest - Frequently Asked Questions What is Acurx Pharmaceuticals' current short interest? Short interest is the volume of Acurx Pharmaceuticals shares that have been sold short but have not yet been covered or closed out. As of February 28th, investors have sold 452,800 shares of ACXP short. 2.67% of Acurx Pharmaceuticals' shares are currently sold short. Learn More on Acurx Pharmaceuticals' current short interest. What is a good short interest ratio for Acurx Pharmaceuticals? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. ACXP shares currently have a short interest ratio of 1.0. Learn More on Acurx Pharmaceuticals's short interest ratio. Which institutional investors are shorting Acurx Pharmaceuticals? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Acurx Pharmaceuticals: Citadel Advisors LLC, and Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Acurx Pharmaceuticals? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 2.67% of Acurx Pharmaceuticals' floating shares are currently sold short. Is Acurx Pharmaceuticals' short interest increasing or decreasing? Acurx Pharmaceuticals saw a increase in short interest in February. As of February 28th, there was short interest totaling 452,800 shares, an increase of 112.2% from the previous total of 213,400 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Acurx Pharmaceuticals' float size? Acurx Pharmaceuticals currently has issued a total of 22,043,000 shares. Some of Acurx Pharmaceuticals' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Acurx Pharmaceuticals currently has a public float of 16,960,000 shares. How does Acurx Pharmaceuticals' short interest compare to its competitors? 2.67% of Acurx Pharmaceuticals' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Acurx Pharmaceuticals: Reviva Pharmaceuticals Holdings, Inc. (15.56%), FibroBiologics, Inc. (7.33%), Alterity Therapeutics Limited (0.96%), Celularity Inc. (8.30%), Cadrenal Therapeutics, Inc. (2.44%), Generation Bio Co. (5.61%), Forte Biosciences, Inc. (0.24%), CASI Pharmaceuticals, Inc. (0.57%), NRx Pharmaceuticals, Inc. (9.09%), Estrella Immunopharma, Inc. (0.22%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Invesco QQQ ($23.74 billion), iShares 20+ Year Treasury Bond ETF ($10.75 billion), MicroStrategy Incorporated ($6.56 billion), Apollo Global Management, Inc. ($5.40 billion), Charter Communications, Inc. ($4.57 billion), AppLovin Co. ($4.45 billion), Capital One Financial Co. ($4.33 billion), Super Micro Computer, Inc. ($4.23 billion), Schlumberger Limited ($3.22 billion), and Royal Caribbean Cruises Ltd. ($3.06 billion). View all of the most shorted stocks. What does it mean to sell short Acurx Pharmaceuticals stock? Short selling ACXP is an investing strategy that aims to generate trading profit from Acurx Pharmaceuticals as its price is falling. ACXP shares are trading down $0.01 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Acurx Pharmaceuticals? A short squeeze for Acurx Pharmaceuticals occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of ACXP, which in turn drives the price of the stock up even further. How often is Acurx Pharmaceuticals' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ACXP, twice per month. The most recent reporting period available is February, 28 2025. More Short Interest Resources from MarketBeat Related Companies Reviva Pharmaceuticals Short Interest FibroBiologics Short Interest Alterity Therapeutics Short Interest Celularity Short Interest Cadrenal Therapeutics Short Interest Generation Bio Short Interest Forte Biosciences Short Interest CASI Pharmaceuticals Short Interest NRx Pharmaceuticals Short Interest Estrella Immunopharma Short Interest Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:ACXP) was last updated on 3/26/2025 by MarketBeat.com Staff From Our PartnersTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredDOGE could send 6 AI stocks through the roofStay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredAlert: DOGE goes liveElon will most likely be at the helm of it all. And just days from now, could bring about the biggest econo...Altimetry | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acurx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acurx Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
